A Scientist’s Journey to Entrepreneurship - The Story of Enleofen
In this part of the Duke-NUS Bio-Entrepreneur series, we will hear about the journey of Dr Sebastian Schaefer, Assistant Professor in Duke-NUS’ Cardiovascular and Metabolic Disorders programme. As a postdoctoral fellow, Dr Schaefer was a co-inventor for a technology that was spun out into a company, Enleofen. Dr Schaefer learned to be a successful entrepreneur on the fly. With assistance from the Duke-NUS Academic Medical Centre's (AMC’s) Joint Centre for Technology and Development, Enleofen’s R&D programme was acquired by Boehringer Ingelheim. Dr Schaefer will share his story of navigating the road to bio-entrepreneurship while balancing academic research. We invite you to join us in this webinar to learn more about finding the “right partners” within the Singapore biotech ecosystem for a successful spin-off. Program:
Q&A sessionSpeaker's Profile:
Sebastian studied biochemical engineering in Erlangen, Busan, and Boston and pursued a Ph.D. in genetics at the Max Delbrück Center in Berlin. During his post-doctoral training in the Cook lab at the National Heart Centre Singapore and Duke-NUS, he investigated the role of Interleukin 11 in a range of fibro-inflammatory diseases. To translate his findings, Sebastian filed several patent applications and co-founded a start-up with funding and support from Singaporean biotech entrepreneurs. His company Enleofen Bio develops first-in-class antibody therapeutics adopting a lean and asset-centric approach. This ensures basic discoveries lead to treatments in a fast and efficient manner and academic research ultimately benefits patients. To further accelerate the program, Enleofen Bio struck a deal with the global pharmaceutical company Boehringer Ingelheim in 2020.Moderator's Profile:
Sabrina has been supporting entrepreneurs for the last 5 years, utilising the skills and experience from her multi-faceted career as an investment banker, strategy consultant and corporate leader. She was the CFO of one of Singapore's leading biotechs, Hummingbird Bioscience, seeing the company grow 10x and from Angel to Series B. She is currently the CFO of CXA Group which is at the confluence of insurtech and healthtech, helping employees get healthier and happier.
Date and Time
21 Oct 2020 @ 11:00 - 21 Oct 2020 @ 12:00